Philadelphia chromosome

Philadelphia chromosome. It is a specific chromosomal abnormality resulting from a reciprocal translocation between chromosome 9 and chromosome 22. This genetic alteration is the defining hallmark of chronic myeloid leukemia and is also found in a subset of acute lymphoblastic leukemia. The discovery of this marker revolutionized the understanding of cancer as a genetic disease and directly led to the development of targeted therapy.

Discovery and history

The abnormality was first identified in 1960 by scientists Peter Nowell and David Hungerford while examining chromosomes from patients with chronic myeloid leukemia at the University of Pennsylvania and the Fox Chase Cancer Center in Philadelphia. Their work, using early cytogenetics techniques, revealed an abnormally small chromosome 22, which they termed the Philadelphia chromosome. This was the first consistent chromosomal abnormality linked to a specific human cancer, a landmark finding in oncology. The precise nature of the reciprocal translocation was later elucidated in 1973 by Janet Rowley at the University of Chicago, who identified the exchange of material between chromosome 9 and chromosome 22.

Genetic characteristics

The Philadelphia chromosome is formed by a reciprocal translocation between the long arms of chromosome 9 and chromosome 22, designated t(9;22)(q34;q11). This event relocates the ABL1 proto-oncogene from chromosome 9 to the breakpoint cluster region on chromosome 22. The fusion creates a novel BCR-ABL1 fusion gene on the derivative chromosome 22. This chimeric gene is transcribed and translated into the BCR-ABL1 fusion protein, a constitutively active tyrosine kinase that drives uncontrolled cell proliferation and inhibits apoptosis. The exact structure of the fusion gene can vary, influencing the disease phenotype.

Role in disease

The Philadelphia chromosome is pathognomonic for nearly all cases of chronic myeloid leukemia, where its presence confirms the diagnosis. It is also found in approximately 20-30% of adult acute lymphoblastic leukemia cases and a small percentage of acute myeloid leukemia. The BCR-ABL1 oncoprotein is the central driver of leukemogenesis, promoting signal transduction pathways that confer a survival and growth advantage to hematopoietic stem cells. The specific breakpoint in the BCR gene influences the molecular weight of the oncoprotein and correlates with disease type, such as the p210 variant in chronic myeloid leukemia and the p190 variant in acute lymphoblastic leukemia.

Diagnostic methods

Detection of the Philadelphia chromosome is a critical component of leukemia diagnosis and classification. Traditional cytogenetics analysis, or karyotyping, of bone marrow cells can visualize the translocation. More sensitive techniques include fluorescence in situ hybridization, which uses labeled probes for the BCR and ABL1 genes to detect the fusion. The gold standard is reverse transcription polymerase chain reaction, which can identify the specific BCR-ABL1 fusion transcript with extremely high sensitivity, allowing for minimal residual disease monitoring. These tests are routinely performed in clinical hematology and molecular pathology laboratories.

Treatment implications

The elucidation of the BCR-ABL1 tyrosine kinase's role led to the development of tyrosine kinase inhibitors, a breakthrough in targeted therapy. The first such agent, imatinib, was developed by Novartis and dramatically improved outcomes for chronic myeloid leukemia, transforming it from a fatal disease into a manageable chronic condition. Subsequent generations of inhibitors, such as dasatinib, nilotinib, bosutinib, and ponatinib, were developed to overcome resistance mutations. Monitoring BCR-ABL1 transcript levels via quantitative PCR is standard for assessing treatment response, with goals defined by international collaborations like the European LeukemiaNet. Category:Chromosomal abnormalities Category:Oncology Category:Hematology